**Core Concept**
The question is testing knowledge of pharmacological agents used in the management of angina, specifically inhibitors of the enzyme **partial fatty acid oxidation (PFO) or more accurately, inhibitors of fatty acid oxidation**. In the context of cardiac disease, these agents can improve myocardial efficiency by shifting energy production from fatty acid to glucose oxidation.

**Why the Correct Answer is Right**
The correct answer is related to **Ranolazine**, which is known for its use in chronic angina. It works by inhibiting the **sodium channel** in cardiac myocytes, but its mechanism also involves the inhibition of **fatty acid oxidation**, thereby reducing intracellular sodium and calcium overload seen in ischemic conditions.

**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect as it is not specified and does not directly relate to the known PFOR inhibitor used in angina management.
**Option B:** Incorrect as it is not the recognized PFOR inhibitor for angina treatment.
**Option C:** Incorrect as it does not match the known drug for this specific use.
**Option D:** Incorrect as it is not the correct choice based on the information provided.

**Clinical Pearl / High-Yield Fact**
Ranolazine is unique among anti-anginal drugs because it does not significantly lower blood pressure or heart rate at therapeutic doses, making it a valuable option for patients who cannot tolerate traditional agents like beta-blockers or calcium channel blockers.

**Correct Answer:** D. Ranolazine